Appropriate use of nevirapine for long-term therapy [1] (multiple letters)

Journal of Infectious Diseases

Volumn 192, Issue 3, 2005, Pages 545-547

  Leith, Jonathan ^a   Piliero, Peter ^b   Storfer, Stephen ^b   Mayers, Douglas ^b   Hinzmann, Ralf ^a   Sanne, Ian ^c   Rousseau, Franck ^d   Bartlett, John A ^e   Lederman, Michael M ^f  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d GILEAD SCIENCES INC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; NEVIRAPINE; STAVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; BODY MASS; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; LABORATORY TEST; LETTER; LIVER TOXICITY; LONG TERM CARE; LYMPHOCYTE COUNT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX RATIO; TOXICITY;

CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LIVER; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 22544487489     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/431606     Document Type: Letter

References (0)